NR 565 ADVANCED PHARMACOLOGY FINAL EXAM
VERSION A & VERSION B (COMBINED)
2026/2027 EDITION
This is an independent practice exam for educational study; it is not an official APCO Institute EMD course final examination.
Exam Overview
This comprehensive final practice exam contains 200 questions in two parallel versions, each with 100 distinct
questions covering the same core topics. Version A runs Q1-Q100 and Version B runs Q101-Q200, aligned with the
Walden University NR 565 curriculum, current FDA/CDC guidelines, evidence-based prescribing standards, and
advanced practice pharmacology competencies for 2026/2027.
Section Topic Per Version
1 Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics 15
2 Autonomic & Central Nervous System Drugs 15
3 Cardiovascular & Renal Pharmacology 15
4 Endocrine & Metabolic Drugs 15
5 Anti-infectives 15
6 Special Populations - Peds, Geri, Pregnancy/Lactation 10
7 Adverse Effects, Drug Interactions, & Black Box Warnings 10
8 Clinical Decision-Making, Prescribing, & Monitoring 5
TOTAL per version / combined
Instructions
For each question, select the single best answer. Use the answer key at the end of the exam to check your work. Each
item includes a brief rationale explaining the correct response.
Answer Key Distribution (each version): 25 A · 25 B · 25 C · 25 D
, VERSION A (Questions 1 - 100)
Section 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics
Q1: The half-life of a drug is the time required for the:
A. Drug to be completely eliminated
B. Plasma concentration to decrease by 50% [CORRECT]
C. Drug to reach peak effect
D. Drug to be absorbed
Correct Answer: B
Rationale: Half-life is the time for plasma concentration to decrease by 50%. The other options are incorrect.
Q2: Steady state is reached after approximately how many half-lives?
A. 4-5 half-lives [CORRECT]
B. 1 half-life
C. 10 half-lives
D. 0.5 half-life
Correct Answer: A
Rationale: Steady state is reached after about 4-5 half-lives. The other options are incorrect.
Q3: Bioavailability refers to:
A. The drug's potency
B. The drug's half-life
C. The drug's receptor affinity
D. The fraction of the administered drug that reaches systemic circulation [CORRECT]
Correct Answer: D
Rationale: Bioavailability is the fraction of drug reaching systemic circulation. The other options are incorrect.
Q4: First-pass metabolism primarily occurs in the:
A. Kidney
B. Lungs
C. Liver [CORRECT]
D. Stomach
Correct Answer: C
Rationale: First-pass metabolism occurs mainly in the liver. The other options are incorrect.
Q5: A drug that is a 'partial agonist' at a receptor:
A. Produces a submaximal response even at full receptor occupancy [CORRECT]
B. Produces no response
C. Blocks the receptor completely
D. Is always toxic
Correct Answer: A
Rationale: A partial agonist produces a submaximal response. The other options are incorrect.
Q6: The therapeutic index is the ratio of:
A. The therapeutic dose to the toxic dose
B. The toxic dose to the therapeutic dose [CORRECT]
C. Absorption to excretion
D. Onset to duration
Correct Answer: B
Rationale: The therapeutic index = TD50/ED50 (toxic dose / therapeutic dose). The other options are incorrect.
Q7: CYP2D6 is an important enzyme in the metabolism of:
A. Only antibiotics
B. Only diuretics
C. Only insulins
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 2
, D. Many antidepressants and antipsychotics [CORRECT]
Correct Answer: D
Rationale: CYP2D6 metabolizes many psychotropics. The other options are incorrect.
Q8: A patient who is a 'poor metabolizer' of CYP2C19 may have:
A. Higher drug levels and increased side-effect risk for substrates [CORRECT]
B. Lower drug levels
C. No effect
D. Faster elimination
Correct Answer: A
Rationale: Poor metabolizers have higher levels of CYP2C19 substrates. The other options are incorrect.
Q9: Pharmacogenomic testing for HLA-B*5701 is recommended before:
A. Abacavir therapy [CORRECT]
B. Penicillin therapy
C. Metformin therapy
D. Aspirin therapy
Correct Answer: A
Rationale: HLA-B*5701 testing is recommended before abacavir to prevent hypersensitivity. The other options are incorrect.
Q10: The volume of distribution (Vd) describes:
A. The drug's potency
B. The drug's half-life
C. The apparent space in the body that contains the drug [CORRECT]
D. The drug's receptor
Correct Answer: C
Rationale: Vd is the apparent volume into which the drug distributes. The other options are incorrect.
Q11: Which CYP450 enzyme is involved in the metabolism of many statins?
A. CYP2D6
B. CYP1A2
C. CYP2E1
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes many statins. The other options are less involved.
Q12: An antagonist at a receptor:
A. Activates the receptor
B. Has a submaximal effect
C. Increases the response
D. Blocks the receptor and prevents an agonist effect [CORRECT]
Correct Answer: D
Rationale: An antagonist blocks receptor activation. The other options describe agonists.
Q13: Renal impairment most directly affects which phase of pharmacokinetics?
A. Excretion [CORRECT]
B. Absorption
C. Distribution
D. Binding
Correct Answer: A
Rationale: Renal impairment affects drug excretion. The other options are less directly affected.
Q14: A loading dose is used to:
A. Rapidly achieve a therapeutic plasma concentration [CORRECT]
B. Slowly titrate
C. Reduce side effects
D. Extend the half-life
Correct Answer: A
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 3
, Rationale: A loading dose quickly achieves therapeutic levels. The other options are incorrect.
Q15: The dose of a renally cleared drug in a patient with severe renal impairment should generally be:
A. Increased
B. Unchanged
C. Doubled
D. Reduced or the interval extended [CORRECT]
Correct Answer: D
Rationale: Renally cleared drugs require dose reduction or interval extension in renal impairment. The other options are unsafe.
Section 2: Autonomic & Central Nervous System Drugs
Q16: Which drug class inhibits acetylcholinesterase and is used for Alzheimer's disease?
A. Cholinesterase inhibitors (e.g., donepezil) [CORRECT]
B. Anticholinergics
C. Beta-blockers
D. SSRIs
Correct Answer: A
Rationale: Cholinesterase inhibitors like donepezil are used for Alzheimer's. The other options are different classes.
Q17: Atropine is an:
A. Cholinergic agonist
B. Anticholinergic (muscarinic antagonist) [CORRECT]
C. Adrenergic agonist
D. Beta-blocker
Correct Answer: B
Rationale: Atropine is an anticholinergic. The other options are incorrect.
Q18: An adverse effect of anticholinergic drugs is:
A. Diarrhea
B. Increased secretions
C. Bradycardia
D. Dry mouth and constipation [CORRECT]
Correct Answer: D
Rationale: Anticholinergics cause dry mouth and constipation. The other options are not anticholinergic effects.
Q19: Which is an adverse effect of beta-agonists (e.g., albuterol)?
A. Bradycardia
B. Hypotension
C. Drowsiness
D. Tachycardia [CORRECT]
Correct Answer: D
Rationale: Beta-agonists can cause tachycardia. The other options are not typical.
Q20: The first-line initial antidepressant class for major depression is:
A. MAOIs
B. TCAs
C. SSRIs [CORRECT]
D. Antipsychotics
Correct Answer: C
Rationale: SSRIs are first-line for depression. The other options are not first-line.
Q21: Serotonin syndrome is a risk when combining an SSRI with:
A. An MAOI or another serotonergic agent [CORRECT]
B. A beta-blocker
C. A diuretic
D. A statin
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 4
VERSION A & VERSION B (COMBINED)
2026/2027 EDITION
This is an independent practice exam for educational study; it is not an official APCO Institute EMD course final examination.
Exam Overview
This comprehensive final practice exam contains 200 questions in two parallel versions, each with 100 distinct
questions covering the same core topics. Version A runs Q1-Q100 and Version B runs Q101-Q200, aligned with the
Walden University NR 565 curriculum, current FDA/CDC guidelines, evidence-based prescribing standards, and
advanced practice pharmacology competencies for 2026/2027.
Section Topic Per Version
1 Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics 15
2 Autonomic & Central Nervous System Drugs 15
3 Cardiovascular & Renal Pharmacology 15
4 Endocrine & Metabolic Drugs 15
5 Anti-infectives 15
6 Special Populations - Peds, Geri, Pregnancy/Lactation 10
7 Adverse Effects, Drug Interactions, & Black Box Warnings 10
8 Clinical Decision-Making, Prescribing, & Monitoring 5
TOTAL per version / combined
Instructions
For each question, select the single best answer. Use the answer key at the end of the exam to check your work. Each
item includes a brief rationale explaining the correct response.
Answer Key Distribution (each version): 25 A · 25 B · 25 C · 25 D
, VERSION A (Questions 1 - 100)
Section 1: Pharmacokinetics, Pharmacodynamics, & Pharmacogenomics
Q1: The half-life of a drug is the time required for the:
A. Drug to be completely eliminated
B. Plasma concentration to decrease by 50% [CORRECT]
C. Drug to reach peak effect
D. Drug to be absorbed
Correct Answer: B
Rationale: Half-life is the time for plasma concentration to decrease by 50%. The other options are incorrect.
Q2: Steady state is reached after approximately how many half-lives?
A. 4-5 half-lives [CORRECT]
B. 1 half-life
C. 10 half-lives
D. 0.5 half-life
Correct Answer: A
Rationale: Steady state is reached after about 4-5 half-lives. The other options are incorrect.
Q3: Bioavailability refers to:
A. The drug's potency
B. The drug's half-life
C. The drug's receptor affinity
D. The fraction of the administered drug that reaches systemic circulation [CORRECT]
Correct Answer: D
Rationale: Bioavailability is the fraction of drug reaching systemic circulation. The other options are incorrect.
Q4: First-pass metabolism primarily occurs in the:
A. Kidney
B. Lungs
C. Liver [CORRECT]
D. Stomach
Correct Answer: C
Rationale: First-pass metabolism occurs mainly in the liver. The other options are incorrect.
Q5: A drug that is a 'partial agonist' at a receptor:
A. Produces a submaximal response even at full receptor occupancy [CORRECT]
B. Produces no response
C. Blocks the receptor completely
D. Is always toxic
Correct Answer: A
Rationale: A partial agonist produces a submaximal response. The other options are incorrect.
Q6: The therapeutic index is the ratio of:
A. The therapeutic dose to the toxic dose
B. The toxic dose to the therapeutic dose [CORRECT]
C. Absorption to excretion
D. Onset to duration
Correct Answer: B
Rationale: The therapeutic index = TD50/ED50 (toxic dose / therapeutic dose). The other options are incorrect.
Q7: CYP2D6 is an important enzyme in the metabolism of:
A. Only antibiotics
B. Only diuretics
C. Only insulins
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 2
, D. Many antidepressants and antipsychotics [CORRECT]
Correct Answer: D
Rationale: CYP2D6 metabolizes many psychotropics. The other options are incorrect.
Q8: A patient who is a 'poor metabolizer' of CYP2C19 may have:
A. Higher drug levels and increased side-effect risk for substrates [CORRECT]
B. Lower drug levels
C. No effect
D. Faster elimination
Correct Answer: A
Rationale: Poor metabolizers have higher levels of CYP2C19 substrates. The other options are incorrect.
Q9: Pharmacogenomic testing for HLA-B*5701 is recommended before:
A. Abacavir therapy [CORRECT]
B. Penicillin therapy
C. Metformin therapy
D. Aspirin therapy
Correct Answer: A
Rationale: HLA-B*5701 testing is recommended before abacavir to prevent hypersensitivity. The other options are incorrect.
Q10: The volume of distribution (Vd) describes:
A. The drug's potency
B. The drug's half-life
C. The apparent space in the body that contains the drug [CORRECT]
D. The drug's receptor
Correct Answer: C
Rationale: Vd is the apparent volume into which the drug distributes. The other options are incorrect.
Q11: Which CYP450 enzyme is involved in the metabolism of many statins?
A. CYP2D6
B. CYP1A2
C. CYP2E1
D. CYP3A4 [CORRECT]
Correct Answer: D
Rationale: CYP3A4 metabolizes many statins. The other options are less involved.
Q12: An antagonist at a receptor:
A. Activates the receptor
B. Has a submaximal effect
C. Increases the response
D. Blocks the receptor and prevents an agonist effect [CORRECT]
Correct Answer: D
Rationale: An antagonist blocks receptor activation. The other options describe agonists.
Q13: Renal impairment most directly affects which phase of pharmacokinetics?
A. Excretion [CORRECT]
B. Absorption
C. Distribution
D. Binding
Correct Answer: A
Rationale: Renal impairment affects drug excretion. The other options are less directly affected.
Q14: A loading dose is used to:
A. Rapidly achieve a therapeutic plasma concentration [CORRECT]
B. Slowly titrate
C. Reduce side effects
D. Extend the half-life
Correct Answer: A
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 3
, Rationale: A loading dose quickly achieves therapeutic levels. The other options are incorrect.
Q15: The dose of a renally cleared drug in a patient with severe renal impairment should generally be:
A. Increased
B. Unchanged
C. Doubled
D. Reduced or the interval extended [CORRECT]
Correct Answer: D
Rationale: Renally cleared drugs require dose reduction or interval extension in renal impairment. The other options are unsafe.
Section 2: Autonomic & Central Nervous System Drugs
Q16: Which drug class inhibits acetylcholinesterase and is used for Alzheimer's disease?
A. Cholinesterase inhibitors (e.g., donepezil) [CORRECT]
B. Anticholinergics
C. Beta-blockers
D. SSRIs
Correct Answer: A
Rationale: Cholinesterase inhibitors like donepezil are used for Alzheimer's. The other options are different classes.
Q17: Atropine is an:
A. Cholinergic agonist
B. Anticholinergic (muscarinic antagonist) [CORRECT]
C. Adrenergic agonist
D. Beta-blocker
Correct Answer: B
Rationale: Atropine is an anticholinergic. The other options are incorrect.
Q18: An adverse effect of anticholinergic drugs is:
A. Diarrhea
B. Increased secretions
C. Bradycardia
D. Dry mouth and constipation [CORRECT]
Correct Answer: D
Rationale: Anticholinergics cause dry mouth and constipation. The other options are not anticholinergic effects.
Q19: Which is an adverse effect of beta-agonists (e.g., albuterol)?
A. Bradycardia
B. Hypotension
C. Drowsiness
D. Tachycardia [CORRECT]
Correct Answer: D
Rationale: Beta-agonists can cause tachycardia. The other options are not typical.
Q20: The first-line initial antidepressant class for major depression is:
A. MAOIs
B. TCAs
C. SSRIs [CORRECT]
D. Antipsychotics
Correct Answer: C
Rationale: SSRIs are first-line for depression. The other options are not first-line.
Q21: Serotonin syndrome is a risk when combining an SSRI with:
A. An MAOI or another serotonergic agent [CORRECT]
B. A beta-blocker
C. A diuretic
D. A statin
NR 565 Advanced Pharmacology Final - Version A & B - 2026/2027 Page 4
